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Hosting 222 participants from more than 25 countries, the Seventh International Conference
on Vaccines for Enteric Diseases (VED 2013) displayed the considerable progress that has
been made in recent years towards unraveling the burden and etiology of enteric infections,
alongside advances in the development, testing and implementation of vaccines that target
them. The pervasive nature of enteric diseases, and the significant morbidity and mortality
they account for, underscore the substantial public health benefits achievable through the
use of enteric vaccines. A number of key talking points raised during the conference are
discussed here, including early experiences with the use of double-mutant heat-labile
enterotoxin as an antigen and adjuvant, progress and challenges associated with the
implementation of oral cholera vaccines, and the issue of impaired rotavirus vaccine
immunogenicity in lower-income countries.
Burden & epidemiology of enteric
diseases
Enteric diseases have long been recognized as a
significant public health concern. However,
recent years have seen a notable shift in our
understanding of the extent and subtle nature
of this burden. As highlighted by Myron M
Levine (University of Maryland, Baltimore,
MD, USA), the Global Enteric Multicenter
Study (GEMS) – a project examining the bur-
den and major etiologies of diarrhea in sub-
Saharan Africa and south Asia – has empha-
sized the common occurrence of putative
enteric pathogens not only among diarrheal
cases, but also in nondiarrheal controls [1].
What, then, distinguishes the individuals who
suffer (often severely) at the hands of a partic-
ular enteric infection from those who do not?
Levine discussed the challenges posed by this
question and noted that by estimating the
attributable fraction of the overall diarrheal
disease burden for each of a multitude of
pathogens, it has been possible to shed light
on the major players of diarrheal disease mor-
bidity in infancy. In the first year of life, for
instance, rotavirus was observed to account for
the largest attributable fraction of moderate-to-
severe diarrhea, followed by Cryptosporidium,
enterotoxigenic Escherichia coli (ETEC) and
Shigella [1].
Dennis Lang (National Institutes of Health,
Bethesda, MD, USA) subsequently described
the progress of the ongoing Malnutrition and
Enteric Diseases (MAL-ED) project – a multi-
center cohort study examining the relationship
between malnutrition, enteric infections, vac-
cine performance and child development in
eight low- and middle-income countries [2].
Like GEMS, the MAL-ED study’s early find-
ings have highlighted the frequent occurrence
of enteric pathogens within both diarrheal and
nondiarrheal stool samples. Lang also noted
the frequent detection of multiple infections,
with as many as seven putative pathogens
observed per sample. By highlighting the per-
vasive and ‘often cryptic’ nature of enteric
infections, the opening presentations by Levine
and Lang laid down the gauntlet for the field
of enteric vaccine research.
James Platts-Mills (University of Virginia,
Charlottesville, VA, USA) followed these pre-
sentations by describing recent developments
in the use of TaqMan array cards – a real-time
quantitative PCR-based assay that enables the
simultaneous detection of multiple enteric
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pathogens [3]. As emphasized by Platts-Mills, not all nucleic
acid amplification is created equal: there is a balance between
overdetection of pathogens by sensitive PCR-based techniques
and the detection of clinically relevant infections. An impor-
tant challenge, therefore, lies in determining this ‘sweet spot’
of pathogen detection. Given the prevalence of mixed infec-
tions highlighted by the GEMS and MAL-ED results, the
array cards and similar technologies are poised to play a key
role in enabling the complex etiologies of diarrheal disease to
be unraveled.
Vaccine developments: talking points from VED 2013
The conference’s remaining program focused on recent develop-
ments in a range of enteric vaccines, with specific sessions devoted
to ETEC, typhoid, Shigella, cholera, rotavirus, noroviruses and
neglected enteric pathogens. Talks ranged in scope from the path-
ogenesis and genetic diversity of the infectious agents to progress
in clinical trials and implementation of various vaccines. With as
many as eight talks per session, this brief review will certainly fall
short of capturing the range of advances and insights discussed.
A selection of key talking points is outlined as follows.
Double-mutant heat-labile enterotoxin: less is more?
As noted by Wilbur H Chen (University of Maryland, Balti-
more, MD, USA), heat-labile enterotoxin (LT) derived from
ETEC is an antigen of significant interest not only for its
potential role within a complete ETEC vaccine, but also for its
adjuvanticity. Chen described the development of double-
mutant LT (dmLT) after a single-mutant variant proved too
reactogenic in early trials. A Phase I trial was then described in
which a single oral dose of dmLT was delivered to healthy
adults at one of four levels (5, 25, 50 or 100 mg) [4]. The mod-
ified toxin was well tolerated at all doses and was immunogenic
at both 50 and 100 mg. However, Chen noted that a consistent
(albeit generally nonsignificant) trend toward a stronger
immune response in 50 mg compared with 100 mg dmLT
recipients was evident in a range of systemic and mucosal
immune correlates, raising the possibility that the immunoge-
nicity of dmLT may plateau with increasing dose.
The application of dmLT as an adjuvant was then described
by Anna Lundgren (University of Gothenburg, Gothenburg,
Sweden), who presented the results of a recent Phase I, double-
blinded, placebo-controlled trial of a novel oral vaccine com-
prising the recombinant B subunit protein LCTBA alongside
four inactivated ETEC strains overexpressing the colonization
factors CS3, CS5, CS6 and CFA/I. Two doses of the vaccine
were administered to healthy adults either alone, together with
dmLT at a low or high dose, or with placebo. The vaccine was
safe and well tolerated, and mucosal IgA antibody responses to
all components of the vaccine were observed in approximately
75% of recipients. Notably, while no clear adjuvanticity was
evident for dmLT overall, a trend toward enhanced immunoge-
nicity was apparent in low-dose dmLT recipients. The findings
were therefore consistent with the notion that the adjuvanticity
of dmLT may be more potent at lower doses.
As noted by Clayton Harro (Johns Hopkins University,
Baltimore, MD, USA), dmLT is the ‘new kid on the block’ of
ETEC vaccine research. The coming years will undoubtedly see
further insights into its potential value and optimal dose as an
antigen and adjuvant.
Experiences in cholera vaccine implementation
The conference’s second day concluded with a special sympo-
sium on oral cholera vaccine (OCV) implementation. David
Sack (Johns Hopkins University, Baltimore, MD, USA) intro-
duced the session by highlighting recent landmarks for OCV,
including the establishment of a vaccine stockpile by the
WHO, the consideration of OCV for GAVI support and the
delivery of more than 1.5 million doses of the licensed vaccines
Dukoral
TM
and Shanchol
TM
. Firdausi Qadri (International Cen-
tre for Diarrhoeal Disease Research, Dhaka, Bangladesh) then
discussed a recent feasibility study for the use of Shanchol in
Bangladesh [5]. The study involved delivery of more than
260,000 doses of OCV in urban Dhaka and further vaccina-
tions in rural Keraniganj. While satisfactory coverage was
obtained during the study, Qadri highlighted some of the oper-
ational challenges encountered during the scale-up of OCV
delivery, including the substantial training requirements and (in
particular) difficulties with cold chain management. These sen-
timents were echoed by Binod Sah (International Vaccine Insti-
tute, Seoul, Republic of Korea), who described a pilot study
undertaken in the state of Odisha, India. In addition to chal-
lenges with cold chain maintenance, Sah discussed issues with
vaccine packaging, as well as the less-than-pleasant taste and
smell of the vaccine, which were among the key obstacles faced
in reaching the desired coverage within the trial.
Subsequent presentations in the symposium highlighted the
wide variety of settings in which OCV has been implemented,
including the Mae La refugee camp in Thailand, urban and
rural Haiti, and as part of Vietnam’s national immunization
program. Despite the challenges identified, the presentations
emphasized the good acceptability of OCV and the potential
to obtain adequate vaccine coverage in each setting. Dipika Sur
(National Institute of Cholera and Enteric Diseases, Kolkata,
India) also presented findings of a placebo-controlled, cluster-
randomized trial of Shanchol carried out in Kolkata, India, in
which two doses of the killed whole-cell vaccine were found to
have a cumulative 5-year efficacy of 65% in preventing Vibrio
cholerae serogroup O1 diarrhea severe enough to require treat-
ment [6]. Overall, OCV implementation was highlighted as a
feasible strategy to complement and enhance cholera prevention
efforts.
Determinants of rotavirus vaccine immunogenicity
A recurring theme in the session on rotavirus vaccines was the
issue of impaired vaccine immunogenicity and efficacy in lower-
income settings. Reasons for this trend remain unclear, though
malnutrition, maternal antibodies, environmental enteropathy
and interference by concurrent oral poliovirus vaccine delivery
are suspected to play a role. S Asad Ali (Aga Khan University,
Meeting Report Parker
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Karachi, Pakistan) described a series of trials carried out in Kar-
achi, Pakistan, to examine the possible influence of alternative
vaccine delivery schedules (6 and 10 week, 10 and 14 week or
6, 10 and 14 week delivery) and temporary withholding of
breastfeeding on seroconversion rates following Rotarix
administration. No significant differences in seroconversion
rates or antirotavirus antibody titers were observed for the
different schedules, while withholding breastfeeding was not
associated with a boost in vaccine response. Similarly, the
temporary withholding of breastfeeding had no impact on
seroconversion rates in a trial of Rotarix recently conducted
in Bangladesh (K Zaman, International Centre for Diarrhoeal
Disease Research, Dhaka, Bangladesh).
Jacob John (Christian Medical College, Vellore, India) then
described a trial conducted in Vellore, India, in which the
effects of zinc and/or probiotic supplementation on seroconver-
sion following two doses of Rotarix were examined. John drew
attention to the higher-than-expected baseline rotavirus seroposi-
tivity observed in the study, alongside the poorer-than-expected
vaccine response. Overall, zinc supplementation had no impact
on rotavirus seroconversion, while probiotic supplementation
was associated with an increase in seroconversion, albeit nonsig-
nificant. The potential impact of zinc or probiotic supplementa-
tion on rotavirus vaccine efficacy remains uncertain.
Together, these and other presentations in the session
highlighted the uncertainties that remain in our understanding
of the determinants of rotavirus vaccine immunogenicity, and
the further work that will be required to resolve the factors
responsible for the impaired performance of the vaccine in
lower-income settings.
The road ahead
Following a plenary presentation by John Mekalanos (Harvard
University, Cambridge, MA, USA) highlighting several aspects
of bacterial pathogenesis that might be harnessed in the next
generation of enteric vaccines (e.g., the type VI secretion sys-
tem), Thomas Brewer (Bill & Melinda Gates Foundation, Seat-
tle, WA, USA) closed the conference by highlighting the huge
variety and depth of materials presented. Brewer drew attention
to the key milestones achieved in recent years, including the
invaluable insights gained from GEMS, significant progress in
the implementation of OCV and a growing appreciation of the
‘multiple pathogen concept’ in our consideration of enteric
infections.
In a field noted by Brewer to be ‘growing at a fairly expo-
nential rate’, these advances form a firm platform on which to
better tackle the considerable morbidity and mortality attribut-
able to enteric diseases.
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